Former Chief Financial Officer · Cerevel Therapeutics Holdings, Inc. (CERE)

Kathy Yi

FY2021 is the first fiscal year CompBrief holds for Kathy Yi as a named executive officer of Cerevel Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$3,501,169

Salary $384,710Stock awards $0

3rd of 7 named executive officers at Cerevel Therapeutics by FY2021 total.

7 named officers on file for Cerevel Therapeutics, FY2021

Kathy Yi’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • CERE’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cerevel Therapeutics’s whole pay program stands against its peers

  • Cerevel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CERE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Kathy Yi’s full pay file as a PDF — free

More than this page: up to 10 years of Kathy’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kathy Yi compensation by year

Cerevel Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Cerevel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$384,710
Bonus$0
Stock awards$0
Option awards$2,720,766
Non-equity incentive$0
Pension and deferred compensation$0
All other$395,693
Total$3,501,169

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cerevel Therapeutics Holdings, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127554, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cerevel Therapeutics Holdings, Inc. filed document, accession 0001193125-22-127554. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Cerevel Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
N. Anthony ColesChairperson and Chief Executive Officer (1)$8,108,335
Abraham CeesayPresident$5,276,631
Kathy Yi · this pageFormer Chief Financial Officer$3,501,169
Raymond SanchezChief Medical Officer$3,416,287
Scott AkamineChief Legal Officer and Corporate Secretary$3,194,740
John RengerChief Scientific Officer$3,093,750
Mark BodenraderInterim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer$1,312,994

The full Cerevel Therapeutics compensation record

free company brief

This page is one person within Cerevel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cerevel Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cerevel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kathy Yi's compensation dossier · One-time report. No refunds.